iShares Biotechnology ETF (IBB)
| Assets | $8.56B |
| Expense Ratio | 0.44% |
| PE Ratio | 24.10 |
| Shares Out | 50.60M |
| Dividend (ttm) | $0.27 |
| Dividend Yield | 0.16% |
| Ex-Dividend Date | Sep 16, 2025 |
| Payout Ratio | 3.76% |
| 1-Year Return | +21.43% |
| Volume | 1,133,099 |
| Open | 172.30 |
| Previous Close | 172.11 |
| Day's Range | 170.49 - 172.79 |
| 52-Week Low | 107.43 |
| 52-Week High | 174.40 |
| Beta | 0.76 |
| Holdings | 252 |
| Inception Date | Feb 5, 2001 |
About IBB
Fund Home PageThe iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the NYSE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is issued by BlackRock.
Top 10 Holdings
48.70% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 7.72% |
| Vertex Pharmaceuticals Incorporated | VRTX | 7.61% |
| Gilead Sciences, Inc. | GILD | 7.11% |
| Regeneron Pharmaceuticals, Inc. | REGN | 6.16% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 4.95% |
| Insmed Incorporated | INSM | 3.56% |
| argenx SE | ARGX | 3.31% |
| IQVIA Holdings Inc. | IQV | 3.19% |
| Natera, Inc. | NTRA | 2.63% |
| Mettler-Toledo International Inc. | MTD | 2.45% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 16, 2025 | $0.08284 | Sep 19, 2025 |
| Mar 18, 2025 | $0.12117 | Mar 21, 2025 |
| Dec 17, 2024 | $0.06237 | Dec 20, 2024 |
| Sep 25, 2024 | $0.20047 | Sep 30, 2024 |
| Mar 21, 2024 | $0.12599 | Mar 27, 2024 |
| Dec 20, 2023 | $0.12396 | Dec 27, 2023 |
News
3 Potential Mid-Cap Biotech Buyout Targets In 2026
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks ...
iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector
The biotech sector, represented by the iShares Biotechnology ETF, has experienced a notable rally in recent months. The key driver of the 40% over the past six months has been a notable uptick in M&A ...
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
'Fast Money' traders talk how to play biopharma space
The 'Fast Money' traders talk how to play biopharma space.
Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson
Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals
Acquired 77,000 shares, valued at $11.1 million Transaction represents 8.7% of 13F reportable AUM Post-trade position: 77,000 shares valued at $11.1 million IBB is now the fund's 2nd-largest holding, ...
Trade Tracker: Jason Snipe buys the IBB
Jason Snipe, Founder and CIO of Odyssey Capital Advisors joins CNBC's “Halftime Report” to detail his latest purchase of the IBB.
Destiny Wealth Sells $8.1 Million in IBB Shares — Here's Why Biotech Stocks Are Lagging
Destiny Wealth Partners reported in an SEC filing on Monday that it sold 59,354 shares of the iShares Biotechnology ETF (IBB) in the third quarter—an estimated $8.1 million transaction based on averag...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from d...
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH
Biotech is entering a new growth cycle driven by AI and CRISPR innovation, but current ETF valuations are high and volatility is elevated. BBH offers a concentrated portfolio of leading innovators wit...
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.
Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff
A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI
IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar o...
5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs
The Big Beautiful Bill boosts defense, industrials, and manufacturing, but healthcare and some REITs face headwinds from Medicaid cuts and policy shifts. AI optimism and the new legislation are fuelin...
Fast Money: WTI, IBB, UBER, CAT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
IBB: Now Is The Time To Be Contrarian
Biotech stocks have underperformed due to sector rotation, rising rates, and regulatory pressures, but I see a contrarian opportunity emerging. A close look at the recent performance of biotech stocks...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.